

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A29; B7, B44, Cw10, Cw16; DR7, DR15; DQ2, DQ6

Summary of Results					Summary of Results			
Total tested	45	45	42	45	32	31	30	31
Positive	45	21	13	2	29	12	2	0
Negative	0	24	29	43	3	19	28	31
Not Tested	6	6	6	6	19	20	20	20
% Positive	100.0%	46.7%	31.0%	4.4%	90.6%	38.7%	6.7%	0.0%
% Negative	0.0%	53.3%	69.0%	95.6%	9.4%	61.3%	93.3%	100.0%

Consensus	Positive	Not Assessed	Not Assessed	Negative	Positive	Not Assessed	Negative	Negative
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B12, B21	A9, B57+	B18+				

Lab No.	Without DTT				With DTT (Pre-pilot - Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
114	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
116	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
117	Positive	Positive	Positive	Negative	NT	NT	NT	NT	
119	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
120	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
126	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
128	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
136	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
139	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
143	Positive	Positive	Negative	Negative	NT	NT	NT	NT	
145	Positive	Positive	Negative	Negative	NT	NT	NT	NT	
147	Positive	Positive	Equivocal	Negative	Positive	Positive	Negative	Negative	
149	Positive	Positive	Positive	Negative	NT	NT	NT	NT	
154	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
159	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
162	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
164	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
169	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
174	Positive	Negative	Equivocal	Negative	Positive	Negative	Equivocal	Negative	
181	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
186	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	
189	Positive	Negative	Negative	Negative	Positive	NT	NT	NT	
190	NT	NT	NT	NT	NT	NT	NT	NT	No cells
193	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Negative	
195	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
197	NT	NT	NT	NT	NT	NT	NT	NT	Very low cell viability. Samples could not be tested.
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
206	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
209	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
210	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
216	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
223	Positive	Positive	Positive	Negative	NT	NT	NT	NT	When we separated the T and B-cells, the content in the tube became flocculent
227	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
229	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
232	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
235	NT	NT	NT	NT	NT	NT	NT	NT	
238	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative	
243	Positive	Positive	Negative	Negative	NT	NT	NT	NT	
245	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
259	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
260	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
262	Positive	Positive	Equivocal	Negative	Positive	Negative	Negative	Negative	
268	Positive	Negative	Positive	Negative	Positive	Positive	Negative	Negative	
271	NT	NT	NT	NT	NT	NT	NT	NT	Not tested due to insufficient reagents
284	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
293	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
294	Positive	Positive	Negative	Negative	NT	NT	NT	NT	
297	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

Lab No.	Without DTT				With DTT (Pre-pilot - Not assessed)				Date received	Date tested	Cells used PBL	T-cells	Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						PBL	T-cells		PBL	T-cells	
112	6	-1	2	-1	2	-1	-1	-1	24-Jan	24-Jan	Yes		No	95		One Lambda	30	60	Stain fix
114	8	1	1	1	8	1	1	1	22-Jan	23-Jan		Yes	Yes			One Lambda	30	60	EB/AO
116	8	6	6	1	8	6	1	1	21-Jan	21-Jan		Yes	No	90		Cedarlane	20	60	EB/AO
117	8	8	8	1					23-Jan	23-Jan	Yes		No	85		Pel-Freeze	60	105	Eosin
119	8	6	4	1	2	1	1	1	22-Jan	23-Jan	Yes			95		Biorad	30	60	Eosin
120	8	1	1	1	6	1	1	1	22-Jan	23-Jan		Yes	Yes	100		Servibio	30	60	EB/AO
126	100%		50%						14-Jan	14-Jan		Yes	Yes	100		Cedarlane	30	40	EB/AO
128	6	1	1	1	1	1	1	1	24-Jan	28-Jan	Yes		No	90		One Lambda	45	90	
136	8	1	6	1					22-Jan	23-Jan	Yes		Yes			In-house	60	60	EB/AO
139	8	6	1	1	8	4	1	1	23-Jan	24-Jan	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin
143	8	4	1	1					23-Jan	24-Jan		Yes	Yes	95		Cedarlane	30	60	Eosin
145	8	6-8							22-Jan	23-Jan		Yes	Yes	100		Invitrogen	45	45	EB/AO
147	8	4	2	1	8	4	1	1	22-Jan	22-Jan		Yes	Yes	100		In-house	30	60	Fluoroquen
149	8	4	2-4						23-Jan	24-Jan	Yes			85			60	60	Eosin
154	8	1	1	1	8	1	1	1	22-Jan	23-Jan		Yes	No	100	95	Cedarlane	30	60	Eosin
159	8				8				23-Jan	23-Jan		Yes	Yes	80		In-house	30	60	Fluoroquen
162	8	8			8	4-6			22-Jan	23-Jan		Yes	Yes	100		Cedarlane	60	60	Fluoroquen
164									22-Jan	23-Jan		Yes	Yes	80		Servibio	45	90	EB/AO
169	8	1	1	1	8	1	1	1	23-Jan	23-Jan		Yes	No	98		One Lambda	35	75	Fluoroquen
174	80%				90-100%				27-Jan	27-Jan	Yes		No	93		One Lambda	60	120	Eosin
181	8	8	2	1	8	8	1	1	22-Jan	22-Jan	Yes			100		Cedarlane	30	45	Fluoroquen
186	8	8	4	0	8	0	0	0	22-Jan	22-Jan		Yes	Yes	99		Invitrogen	30	60	EB
189	8	1	1	1	6	NT	NT	NT	22-Jan	23-Jan	Yes		No	90		Biorad	40	40	EB/AO
190	NT	NT	NT	NT	NT	NT	NT	NT	22-Jan	23-Jan	NT	NT	NT	NT	NT	NT	NT	NT	NT
193	8	6	4	2	8	8	1	1	22-Jan	22-Jan		Yes	No	99		Cedarlane	30	60	Stain fix
195	6	2	2	2					24-Jan	24-Jan	Yes		No	60		Invitrogen	30	60	Fluoroquen
197	NT	NT	NT	NT					NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
202																			
204	8	6	1	1	8	4	1	1	22-Jan	22-Jan		Yes	No	95		Cedarlane	45	90	Fluoroquen
206	8	8	1	1	8	8	1	1	22-Jan	22-Jan		Yes	Yes	100		Cedarlane	30	45	Fluoroquen
209	8				6				23-Jan	23-Jan	Yes		No	90		One Lambda	30	60	Fluoroquen
210	8	0	0	0	8	0	0	0	23-Jan	23-Jan		Yes	Yes	100		Biorad	30	60	
216	8	2	4	2	NT	NT	NT	NT	23-Jan	24-Jan	Yes		No	90		Biorad	30	60	PI
223	8	8	4	1					23-Jan	24-Jan		Yes	Yes	95		Biorad	45	60	EB/AO
227	NT	NT	NT	NT	NT	NT	NT	NT	22-Jan	22-Jan		Yes	Yes	60		GTI Diagnostic	30	60	Fluoroquen
229	100%	40%			100%	40%			23-Jan	24-Jan	Yes		No			Biorad	30	60	
232	70%	0%	0%	0%					23-Jan	24-Jan	Yes		No	80		Biorad	45	60	EB/AO
235																			
238	8	8	4	1	8	8	4	1	23-Jan	23-Jan		Yes	No	99		Invitrogen	45	90	EB
243	8	6	2	2					22-Jan	23-Jan	Yes		Yes	90	90	Biorad	30	60	Fluoroquen
245	6	1	1	1	1	1	1	1	22-Jan	22-Jan	Yes	Yes	Yes	100	100	BAG	30	60	EB/AO
252	6	2	2	2	6	2-4	2	2	24-Jan	24-Jan		Yes	Yes	30-40		Biorad	30	60	
259									23-Jan	23-Jan	Yes	Yes	Yes	20	20	Biorad	30	60	AO/PI
260	++++	-	-	-	+++	-	-	-	23-Jan	23-Jan		Yes	Yes	90		Biorad	30	60	EB/AO
262	8	4		1	8	1	1	1	22-Jan	22-Jan	Yes		No	100		Invitrogen	30	60	Eosin
268	8	1	4	1	8	2	1	1	22-Jan	22-Jan		Yes	No	95		Gentrak	30	60	EB/AO
271	NT	NT	NT	NT	NT	NT	NT	NT	23-Jan	23-Jan	NT	NT	NT	NT	NT	NT	NT	NT	NT
284	8	6	1	1	8	4	1	1	22-Jan	22-Jan		Yes	Yes	99		Cedarlane	40	60	EB/AO
293	6	-	-	-	6	-	-	-	23-Jan	24-Jan		Yes	Yes	70	70	Invitrogen	60	120	
294	8	6	0	0					22-Jan	22-Jan		Yes	Yes	100		Pel-Freeze	30	30	Fluoroquen
297	8	1	1	1	8	1	1	1	22-Jan	23-Jan	Yes	Yes	Yes	90	90	Cedarlane	30	60	EB/AO

AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A24, A29; B7, B44, Cw10, Cw16; DR7, DR15; DQ2, DQ6

Summary of Results					Summary of Results			
Total tested	28	28	28	28	23	22	23	23
Positive	28	17	19	2	22	11	13	0
Negative	0	11	9	26	1	11	10	23
Not Tested	7	7	7	7	12	12	12	12
% Positive	100.0%	60.7%	67.9%	7.1%	95.7%	50.0%	56.5%	0.0%
% Negative	0.0%	39.3%	32.1%	92.9%	4.3%	50.0%	43.5%	100.0%
Consensus	Positive	Not Assessed	Not Assessed	Negative	Positive	Not Assessed	Not Assessed	Negative
HLA Antibody (Defined By CDC)	A3, B7, B27, B22	B12, B21	A9, B57+	B18+				

Lab No.	Without DTT				With DTT (Pre-pilot - Not assessed)				Comments	
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4		
114	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
120	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
126	Positive	Negative	Positive	Negative	NT	NT	NT	NT		
139	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
145	Positive	Positive	Positive	Negative	NT	NT	NT	NT	The evaluation of XM using B-cells were difficult due to the very low number of B-cells	
147	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
154	Positive	Weak Positive	Negative	Negative	Positive	Negative	Negative	Negative		
159	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
162	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
164	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative		
169	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
186	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative		
190	NT	NT	NT	NT	NT	NT	NT	NT		No cells
193	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
195	NT	NT	NT	NT	NT	NT	NT	NT	Too few cells, poor viability	
197	NT	NT	NT	NT	NT	NT	NT	NT	Very low cell viability. Samples could not be tested.	
204	Positive	Positive	Positive	Negative	Positive	Equivocal	Positive	Negative		
206	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
209	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
210	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
223	NT	NT	NT	NT	NT	NT	NT	NT	Not tested due to low viability	
227	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability	
238	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
243	Positive	Positive	Positive	Negative	NT	NT	NT	NT		
245	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative		
252	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
259	Positive	Positive	Positive	Positive	NT	NT	NT	NT		
260	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
262	NT	NT	NT	NT	NT	NT	NT	NT	B-cells not tested due to low cell count before separation	
268	Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative		
271	NT	NT	NT	NT	NT	NT	NT	NT	Not tested due to insufficient reagents	
284	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
293	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		
294	Positive	Positive	Negative	Negative	NT	NT	NT	NT		
297	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative		

PLEASE NOTE: NEXT DISTRIBUTION IS ON TUESDAY 25TH MARCH

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A02/2014

DESPATCHED ON 21ST JANUARY 2014

Lab No.	Without DTT				With DTT (Pre-pilot - Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	8	1	1	1	8	1	1	1	22-Jan	23-Jan	Yes		One Lambda	30	60	EB/AO
120	8	1	1	1	8	1	1	1	22-Jan	23-Jan	Yes	100	Servibio	30	60	EB/AO
126	75%		25%						14-Jan	14-Jan	Yes	100	Cedarlane	30	40	EB/AO
139	8	6	4	1	8	4	4	1	23-Jan	24-Jan	Yes	90	Cedarlane	30	60	Eosin
145	8	8	8						22-Jan	23-Jan	Yes	90	Invitrogen	45	45	EB/AO
147	8	6	4	1	8	4	4	1	22-Jan	22-Jan	Yes	100	In-house	30	60	Fluoroquench
154	8	2	1	1	8	1	1	1	22-Jan	23-Jan	No	95	Cedarlane	30	60	Eosin
159	8	8	8		8	8	8		23-Jan	23-Jan	Yes	60	In-house	30	60	Fluoroquench
162	8	8	8		8	8	8		22-Jan	23-Jan	Yes	85	Cedarlane	60	60	Fluoroquench
164									22-Jan	23-Jan	Yes	80	Servibio	45	90	EB/AO
169	8	1	1	1	8	1	1	1	23-Jan	23-Jan	Yes	98	One Lambda	35	75	Fluoroquench
186	8	8	2	0	8	0	0	0	22-Jan	22-Jan	Yes	99	Invitrogen	30	60	EB
190	NT	NT	NT	NT	NT	NT	NT	NT	22-Jan	23-Jan	NT	NT	NT	NT	NT	NT
193	8	6	6	1	8	6	6	1	22-Jan	22-Jan	Yes	99	Cedarlane	30	60	Hb/PI
195	NT	NT	NT	NT					24-Jan	24-Jan	Yes	20	Invitrogen	60	90	Fluoroquench
197	NT	NT	NT	NT					NT	NT	NT	NT	NT	NT	NT	NT
204	6	4	4	1	8	1-2	2	1	22-Jan	22-Jan	Yes	80	Cedarlane	45	90	Fluoroquench
206	8	8	8	1	8	8	8	1	22-Jan	22-Jan	Yes	100	Cedarlane	30	45	Fluoroquench
209	8				6				23-Jan	23-Jan	Yes	90	One Lambda	30	60	
210	8	0	0	0	8	0	0	0	23-Jan	23-Jan	Yes	90	Biorad	30	60	
223	NT	NT	NT	NT					23-Jan	24-Jan	Yes		Biorad	45	60	EB/AO
227	NT	NT	NT	NT	NT	NT	NT	NT	22-Jan	22-Jan	Yes	20	GTI Diagnostic	30	60	Fluoroquench
238	8	8	6	1	8	8	6	1	22-Jan	23-Jan	Yes	90	Invitrogen	45	90	EB
243	8	6	8	2					22-Jan	23-Jan	Yes	90	Biorad	30	60	Fluoroquench
245	8	1	4	1	1	1	1	1	22-Jan	22-Jan	Yes	100	BAG	30	45	EB/AO
252	4-6	1	2-4	2	6	1	2	2	24-Jan	24-Jan	Yes	20-30	Biorad	30	60	
259									23-Jan	23-Jan	Yes	20	Biorad	30	60	AO/PI
260	++++	-	-	-	++++	-	-	-	23-Jan	23-Jan	Yes	40	Biorad	30	60	EB/AO
262	NT	NT	NT	NT	NT	NT	NT	NT	22-Jan	22-Jan	NT	NT	NT	NT	NT	NT
268	8	1	2	1	8	4	2	1	22-Jan	22-Jan	Yes	95	Gentrak	30	60	EB/AO
271	NT	NT	NT	NT	NT	NT	NT	NT	23-Jan	23-Jan	NT	NT	NT	NT	NT	NT
284	8	8	8	1	8	6	6	1	22-Jan	22-Jan	Yes	98	Cedarlane	40	60	EB/AO
293	6	4	2	-	6	6	2	-	23-Jan	24-Jan	Yes	70	Invitrogen	60	120	
294	8	4	2	0					22-Jan	22-Jan	Yes		Pel-Freeze	30	30	Fluoroquench
297	8	6	8	1	8	4	6	1	22-Jan	23-Jan	Yes	90	Cedarlane	30	60	EB/AO

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate